<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136198</url>
  </required_header>
  <id_info>
    <org_study_id>1R34HL136986-01</org_study_id>
    <nct_id>NCT03136198</nct_id>
  </id_info>
  <brief_title>B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial</brief_title>
  <acronym>BLUSHED-AHF</acronym>
  <official_title>B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inova Fairfax Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nearly 80% of acute heart failure (AHF) patients admitted to the hospital are initially
      treated in the emergency department (ED). Once admitted, within 30 days post-discharge, 27%
      of patients are re-hospitalized or die. Attempts to improve outcomes with novel therapies
      have all failed. The evidence for existing AHF therapies are poor: No currently used AHF
      treatment is known to improve outcomes. ED treatment is largely the same today as 40 years
      ago. Congestion, such as difficulty breathing, weight gain, and leg swelling, is the primary
      reason why patients present to the hospital for AHF. Treating congestion is the cornerstone
      of AHF management. Yet half of all AHF patients leave the hospital inadequately decongested.
      The investigators propose a novel approach to aggressively decongest patients in the ED
      setting: lung ultrasound guided, protocol driven, AHF management. LUS B-lines are a measure
      of extra-vascular lung water (EVLW). In the setting of AHF, LUS B-lines are a measure of
      congestion. This simple, easily learned technique has excellent reliability and
      reproducibility. The investigators hypothesize that a strategy-of-care will outperform usual
      care. At the present time, usual care is largely empirical. This study will improve the
      evidence base for ED AHF management. This proposed pilot study, if successful, will lead to
      an outcome trial examining whether an ED AHF strategy-of-care increases days alive and out of
      the hospital for patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of the BLUSHED AHF pilot trial is to determine whether an early lung
      ultrasound (LUS) guided, protocol-driven ED AHF strategy-of-care leads to more rapid and
      sustained resolution of congestion, as measured by LUS B-lines. If the investigators are able
      to demonstrate this necessary and sufficient information - targeted strategy-of-care is more
      effective than usual care - they will apply for a follow on study to achieve the following
      aim.

      Aim 1: To demonstrate the effectiveness of a targeted decongestion strategy - LUS guided,
      protocol-driven ED AHF management - will result in improved 30-day outcomes vs. usual care.
      This aim will be tested using a randomized, controlled, unblinded, pragmatic, multi-center,
      simple trial design.

      The pilot trial may determine that ED management alone is insufficient to impact the outcome.
      Thus, the investigators may need to modify their subsequent trial design to include targeted
      therapy throughout hospitalization. However, the pilot study will demonstrate whether
      targeted therapy effectively reduces B-lines.

      PUBLIC HEALTH IMPACT Over one million hospitalizations for AHF occur every year in the US.
      Within 30 days after hospitalization, over 25% of AHF patients will be dead or
      re-hospitalized.4 Up to 67% of patients will be re-hospitalized and 36% will be dead by one
      year. For patients aged 65 years and older, AHF is the most common and most expensive reason
      for hospitalization. Despite major reductions in morbidity and mortality for chronic HF,
      considerably less progress has been seen in AHF.

      Congestion is the primary reason why AHF patients present to the ED seeking medical care.
      Congestion is manifest by signs and symptoms of heart failure (HF); dyspnea, orthopnea,
      edema, and weight gain. Yet, how to best assess, grade, and manage congestion is not well
      established.

      Freedom from congestion is associated with improved outcomes; Yet many patients leave the
      hospital inadequately decongested. The absence of robust, reliable methods to assess
      congestion is a primary reason why it is not well-assessed. A recent consensus statement
      published in 2010 highlights this fact: &quot;…no method to assess congestion…has been validated.&quot;
      The investigators would argue many ED AHF patients are poorly assessed prior to treatment. In
      addition, they are poorly re-assessed prior to hospitalization to gauge the success or
      failure of initial management. While physical exam is currently the cornerstone of congestion
      assessment, it lacks sensitivity and inter-rater reliability.

      The investigators challenge the current paradigm of relying on insensitive methods of
      congestion to guide therapy. Furthermore, they argue the lack of a robust evidence base for
      ED management of congestion contributes to poor outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Actual">June 20, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
    <masking_description>A central, independent, Core Lab will review all images.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management</measure>
    <time_frame>During the ED phase of management, usually no more than 6 hours</time_frame>
    <description>B-lines ≤ 15 at the conclusion of ED AHF management or maximum of 6 hours after enrollment, whichever comes first.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Total Days Alive and Out Of Hospital (DAOOH)</measure>
    <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
    <description>Total days alive and out of hospital through 30 and 90 days post-discharge</description>
  </other_outcome>
  <other_outcome>
    <measure>Association of B-lines at Discharge and 30-day / 90-day Outcomes</measure>
    <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Biomarkers From Presentation to Pre-discharge</measure>
    <time_frame>From admission to pre-discharge from the hospital, on average 5 to 7 days.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to Reach B-lines &lt;15</measure>
    <time_frame>Throughout hospitalization, on average 5-7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>B Lines &lt; 15 at 24 Hours and at Discharge</measure>
    <time_frame>Through the first 24 hours and then prior to discharge, on average 5-7 days after admission</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Composite of 30-day and 90-day All-cause Mortality, Cardiovascular (CV) Re-hospitalizations, and CV Emergency Department (ED) Revisits.</measure>
    <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
    <description>CV endpoints are defined according to the 2014 American College of Cardiology/American Heart Association (ACC/AHA) Key Data Elements and Definitions for Cardiovascular Endpoint Events.</description>
  </other_outcome>
  <other_outcome>
    <measure>All Cause Readmissions, All Cause ED Re-visits</measure>
    <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
    <description>30- day and 90-day</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Physical Exam Findings of Heart Failure When Discharge is Compared to Baseline</measure>
    <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
    <description>Physical exam includes body weight, peripheral edema, jugular venous distention, pulmonary and cardiac auscultation</description>
  </other_outcome>
  <other_outcome>
    <measure>Count of Pharmacologic Therapies the Patient Received in the ED</measure>
    <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
    <description>This is a description of which pharmacologic therapies the patient has received.</description>
  </other_outcome>
  <other_outcome>
    <measure>Count of Pharmacologic and Device Therapies the Patient Received During Hospitalization</measure>
    <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
    <description>This is a description of which pharmacologic and device therapies the patient has received.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of LUS Interpretation Within and Between Trained Investigators as Well as the Core Lab</measure>
    <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
    <description>Calculation of intra and inter-agreement between investigators and also the Core Lab to determine the reproducibility of LUS</description>
  </other_outcome>
  <other_outcome>
    <measure>Association of Baseline, Discharge, and Change With 30 and 90 Day Outcomes</measure>
    <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure Acute</condition>
  <condition>Acute Cardiac Pulmonary Edema</condition>
  <condition>Acute Cardiac Failure</condition>
  <arm_group>
    <arm_group_label>LUS-guided strategy-of-care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LUS-guided strategy-of-care</intervention_name>
    <description>For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.
Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)
Reassessment every 2 hours</description>
    <arm_group_label>LUS-guided strategy-of-care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Patients will receive usual AHF care</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Loop Diuretic</intervention_name>
    <description>IV loop diuretic</description>
    <arm_group_label>LUS-guided strategy-of-care</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasodilator</intervention_name>
    <description>IV, topical, or SL Vasodilator</description>
    <arm_group_label>LUS-guided strategy-of-care</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non invasive Ventilation (NIV)</intervention_name>
    <description>Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
    <arm_group_label>LUS-guided strategy-of-care</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 21 years

          -  Presents with shortness of breath at rest or with minimal exertion

          -  Clinical diagnosis of AHF and presence of &gt; 15 total bilateral B-lines distributed in
             at least 4 zones on initial LUS

          -  Hx of chronic HF and any one of the following:

               -  Chest radiograph consistent with AHF

               -  Jugular venous distension

               -  Pulmonary rales on auscultation

               -  Lower extremity edema

        Exclusion Criteria:

          -  Chronic renal dysfunction, including end-stage renal disease (ESRD) or estimated
             glomerular filtration rate (eGFR) &lt; 45ml//min/1.73m2.

          -  Shock of any kind. Any requirement for vasopressors or inotropes.

          -  Systolic blood pressure (SBP) &lt; 100 or &gt;175 mmHg

          -  Need for immediate intubation

          -  Acute Coronary Syndrome- Presentation consistent with myocardial ischemia AND either
             new ST-segment elevation/depression

          -  Fever &gt;101.5 ºF or chest radiograph or clinical picture of pneumonia

          -  End stage HF: transplant list, ventricular assist device

          -  Anemia requiring transfusion

          -  Known interstitial lung disease

          -  Suspected acute lung injury or acute respiratory distress syndrome (ARDS)

          -  Pregnant or recently pregnant within the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter S Pang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eskenazi Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INOVA Health System</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <results_first_submitted>May 5, 2020</results_first_submitted>
  <results_first_submitted_qc>May 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2020</results_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>PETER S PANG</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Acute Heart Failure</keyword>
  <keyword>Pulmonary Edema</keyword>
  <keyword>Lung ultrasound</keyword>
  <keyword>Extra vascular lung water</keyword>
  <keyword>B-lines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03136198/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03136198/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LUS-guided Strategy-of-care</title>
          <description>Patients randomized to the lung ultrasound (LUS) strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
LUS-guided strategy-of-care: For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.
Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)
Reassessment every 2 hours
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
Usual Care: Patients will receive usual AHF care
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LUS-guided Strategy-of-care</title>
          <description>Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
LUS-guided strategy-of-care: For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.
Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)
Reassessment every 2 hours
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
Usual Care: Patients will receive usual AHF care
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="15.9"/>
                    <measurement group_id="B2" value="66.2" spread="12.2"/>
                    <measurement group_id="B3" value="65.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management</title>
        <description>B-lines ≤ 15 at the conclusion of ED AHF management or maximum of 6 hours after enrollment, whichever comes first.</description>
        <time_frame>During the ED phase of management, usually no more than 6 hours</time_frame>
        <population>Out of the 130 participants a total of 8 (5 in the LUS-guided strategy of care arm and 3 in the Usual care arm) had a recorded ED discharge time which was prior to the first LUS, leaving 61 participants in each arm to be analyzed for the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>LUS-guided Strategy-of-care</title>
            <description>Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
LUS-guided strategy-of-care: For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.
Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)
Reassessment every 2 hours
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
Usual Care: Patients will receive usual AHF care
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management</title>
          <description>B-lines ≤ 15 at the conclusion of ED AHF management or maximum of 6 hours after enrollment, whichever comes first.</description>
          <population>Out of the 130 participants a total of 8 (5 in the LUS-guided strategy of care arm and 3 in the Usual care arm) had a recorded ED discharge time which was prior to the first LUS, leaving 61 participants in each arm to be analyzed for the primary outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Days Alive and Out Of Hospital (DAOOH)</title>
        <description>Total days alive and out of hospital through 30 and 90 days post-discharge</description>
        <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Association of B-lines at Discharge and 30-day / 90-day Outcomes</title>
        <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Biomarkers From Presentation to Pre-discharge</title>
        <time_frame>From admission to pre-discharge from the hospital, on average 5 to 7 days.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Reach B-lines &lt;15</title>
        <time_frame>Throughout hospitalization, on average 5-7 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>B Lines &lt; 15 at 24 Hours and at Discharge</title>
        <time_frame>Through the first 24 hours and then prior to discharge, on average 5-7 days after admission</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Composite of 30-day and 90-day All-cause Mortality, Cardiovascular (CV) Re-hospitalizations, and CV Emergency Department (ED) Revisits.</title>
        <description>CV endpoints are defined according to the 2014 American College of Cardiology/American Heart Association (ACC/AHA) Key Data Elements and Definitions for Cardiovascular Endpoint Events.</description>
        <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>All Cause Readmissions, All Cause ED Re-visits</title>
        <description>30- day and 90-day</description>
        <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Physical Exam Findings of Heart Failure When Discharge is Compared to Baseline</title>
        <description>Physical exam includes body weight, peripheral edema, jugular venous distention, pulmonary and cardiac auscultation</description>
        <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Count of Pharmacologic Therapies the Patient Received in the ED</title>
        <description>This is a description of which pharmacologic therapies the patient has received.</description>
        <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Count of Pharmacologic and Device Therapies the Patient Received During Hospitalization</title>
        <description>This is a description of which pharmacologic and device therapies the patient has received.</description>
        <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Comparison of LUS Interpretation Within and Between Trained Investigators as Well as the Core Lab</title>
        <description>Calculation of intra and inter-agreement between investigators and also the Core Lab to determine the reproducibility of LUS</description>
        <time_frame>From admission throughout hospitalization, usually 5-7 days.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Association of Baseline, Discharge, and Change With 30 and 90 Day Outcomes</title>
        <time_frame>Up through 90 days, with specific reporting of events through 30 and 90 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days from consent</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LUS-guided Strategy-of-care</title>
          <description>Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
LUS-guided strategy-of-care: For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.
Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)
Reassessment every 2 hours
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
Usual Care: Patients will receive usual AHF care
Intravenous Loop Diuretic: IV loop diuretic
Vasodilator: IV, topical, or SL Vasodilator
Non invasive Ventilation (NIV): Face, mouth, or nasal mask applied to provide positive pressure ventilation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>NSTEMI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Mitral Regurgitation, severe</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Gross hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>MGUS, new diagnosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>NSTEMI type 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Supratherapeutic digoxin level</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nonsustained ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Mural thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Asymptomatic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Subject was re-admitted due to abdominal pain caused by constipation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>Deep vein thrombosis and pulmonary embolism</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter S. Pang</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-880-3900</phone>
      <email>ppang@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

